Antiviral research

(Antiviral Res) ISSNs: , 1872-9096

References in Antiviral research:

Search this table:

Title	Authors	Year
Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system.	Jegede O, Khodyakova A, Chernov M, Weber J, Menéndez-Arias L, Gudkov A, Quiñones-Mateu ME	2011
Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.	Hachiya A, Shimane K, Sarafianos SG, Kodama EN, Sakagami Y, Negishi F, Koizumi H, Gatanaga H, Matsuoka M, Takiguchi M, Oka S	2009
In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).	Foli A, Sogocio KM, Anderson B, Kavlick M, Saville MW, Wainberg MA, Gu Z, Cherrington JM, Mitsuya H, Yarchoan R	1996
Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127.	Zhang H, Vrang L, Bäckbro K, Lind P, Sahlberg C, Unge T, Oberg B	1995
Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants.	Pelosi E, Mulamba GB, Coen DM	1998
Genotypic characterization of herpes simplex virus DNA polymerase UL42 processivity factor.	Burrel S, Aït-Arkoub Z, Agut H, Boutolleau D	2012
Slow binding-tight binding interaction between benzimidazol-2-one inhibitors and HIV-1 reverse transcriptase containing the lysine 103 to asparagine mutation.	Samuele A, Crespan E, Vitellaro S, Monforte AM, Logoteta P, Chimirri A, Maga G	2010
The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy.	Coen DM	1991
Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus.	Suzuki M, Okuda T, Shiraki K	2006
Novel L-lyxo and 5'-deoxy-5'-modified TSAO-T analogs: synthesis and anti-HIV-1 activity.	Ingate S, De Clercq E, Balzarini J, Camarasa MJ	1996
Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model.	Hantz S, Cotin S, Borst E, Couvreux A, Salmier A, Garrigue I, Merville P, Mengelle C, Attal M, Messerle M, Alain S	2013
Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.	Samuele A, Kataropoulou A, Viola M, Zanoli S, La Regina G, Piscitelli F, Silvestri R, Maga G	2009
NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.	Paolucci S, Baldanti F, Campanini G, Cancio R, Belfiore A, Maga G, Gerna G	2007
Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.	Loemba H, Brenner BG, Parniak MA, Ma'ayan S, Spira B, Moisi DD, Oliveira M, Detorio M, Essex M, Wainberg MA	2002
2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.	Rao A, Balzarini J, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappalà M	2004
Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro.	Rübsamen-Waigmann H, Huguenel E, Shah A, Paessens A, Ruoff HJ, von Briesen H, Immelmann A, Dietrich U, Wainberg MA	1999
Therapeutic strategies towards HIV-1 infection in macrophages.	Perno CF, Svicher V, Schols D, Pollicita M, Balzarini J, Aquaro S	2006
Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxynucleosides.	Martin JC, Hitchcock MJ, De Clercq E, Prusoff WH	2010
Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains.	Balzarini J, Brouwer WG, Felauer EE, De Clercq E, Karlsson A	1995
2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections.	Snoeck R, Andrei G, Bodaghi B, Lagneaux L, Daelemans D, De Clercq E, Neyts J, Schols D, Naesens L, Michelson S, Bron D, Otto MJ, Bousseau A, Nemecek C, Roy C	2002
In vitro evaluation of the effect of temporary removal of HIV drug pressure.	Witvrouw M, Pannecouque C, Desmyter J, De Clercq E, Andries K	2000
Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)].	Ito M, Nakashima H, Baba M, Pauwels R, De Clercq E, Shigeta S, Yamamoto N	1987
Selective inhibition of Human Immunodeficiency Virus type 1 (HIV-1) by a novel family of tricyclic nucleosides.	Bonache MC, Cordeiro A, Quesada E, Vanstreels E, Daelemans D, Camarasa MJ, Balzarini J, San-Félix A	2011
Comparative evaluation of the activity of antivirals towards feline immunodeficiency virus in different cell culture systems.	van der Meer FJ, Schuurman NM, Balzarini J, Egberink HF	2007
Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir.	Aquaro S, Caliò R, Balzarini J, Bellocchi MC, Garaci E, Perno CF	2002
Antiviral drug discovery and development: where chemistry meets with biomedicine.	De Clercq E	2005
Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir.	Ying C, Colonno R, De Clercq E, Neyts J	2007
In search of a selective therapy of viral infections.	De Clercq E	2010
Antiviral properties of new arylsulfone derivatives with activity against human betaherpesviruses.	Naesens L, Stephens CE, Andrei G, Loregian A, De Bolle L, Snoeck R, Sowell JW, De Clercq E	2006
Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives.	Neyts J, De Clercq E	2003
The anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)-cycloprop-1'-yl]methyl]guanine is markedly potentiated by the immunosuppressive agent mycophenolate mofetil.	Neyts J, De Clercq E	2001
Suramin in the treatment of AIDS: mechanism of action.	De Clercq E	1987
Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus.	Ying C, De Clercq E, Neyts J	2000
New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase.	Bellarosa D, Antonelli G, Bambacioni F, Giannotti D, Viti G, Nannicini R, Giachetti A, Dianzani F, Witvrouw M, Pauwels R, Desmyter J, De Clercq E	1996
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.	De Clercq E	1998
Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1.	Esté JA, De Vreese K, Witvrouw M, Schmit JC, Vandamme AM, Anné J, Desmyter J, Henson GW, Bridger G, De Clercq E	1996
Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes?	Camarasa MJ, Velázquez S, San-Félix A, Pérez-Pérez MJ, Gago F	2006
Phosphorylation of nucleoside analogs by equine herpesvirus type 1 pyrimidine deoxyribonucleoside kinase.	Kit S, Ichimura H, De Clercq E	1987
In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?	Andrei G, De Clercq E, Snoeck R	2004

Showing 1 to 39 of 39 entries